Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022
August 04, 2022 08:30 ET
|
Biofrontera Inc.
WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will...
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
August 01, 2022 11:00 ET
|
Biofrontera Inc.
Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduced Pain Intensity while Maintaining Efficacy WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI),...
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
July 27, 2022 08:45 ET
|
Biofrontera Inc.
WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it has...
Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022
July 12, 2022 08:00 ET
|
Biofrontera Inc.
WOBURN, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today...
Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence
June 09, 2022 09:44 ET
|
Biofrontera Inc.
Named Among the 10 Fastest-Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine New Ameluz® Marketing Campaign Receives Gold 2022 Award of Excellence from The Communicator...
Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference
May 31, 2022 10:42 ET
|
Biofrontera Inc.
WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera’s Ameluz®
May 24, 2022 11:29 ET
|
Biofrontera Inc.
WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin...
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
May 19, 2022 09:48 ET
|
Biofrontera Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement
May 16, 2022 08:00 ET
|
Biofrontera Inc.
WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor...
Biofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update
May 13, 2022 07:00 ET
|
Biofrontera Inc.
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing...